公开(公告)号：US09834504B2

公开(公告)日：2017-12-05

申请号：US15100718

申请日：2014-12-08

申请人： GE Healthcare AS

发明人： Torfinn Haaland ,  Arne Askildsen ,  Rita Heskestad Kalleberg ,  Sumihar Silalahi ,  Alf Martin Farbrot ,  Inger Dagny Saanum

IPC分类号： C07C231/24 ,  C07C231/02 ,  C07C237/46

CPC分类号： C07C231/24 ,  C07C231/02 ,  C07C237/46

摘要： Alternative continuous downstream processes for the production of 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.

公开(公告)号：US09695113B2

公开(公告)日：2017-07-04

申请号：US15100818

申请日：2014-12-08

申请人： GE Healthcare AS

发明人： Torfinn Haaland ,  Arne Askildsen ,  Rita Heskestad Kalleberg ,  Sumihar Silalahi ,  Alf Martin Farbrot ,  Inger Dagny Saanum

IPC分类号： C07C231/24 ,  C07C231/02 ,  C07C237/46

CPC分类号： C07C231/24 ,  C07C231/02 ,  C07C237/46

摘要： Alternative continuous downstream processes for the production of 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.

公开(公告)号：US20230133715A1

公开(公告)日：2023-05-04

申请号：US17912646

申请日：2021-03-31

申请人： GE Healthcare AS

发明人： Torfinn Haaland ,  Arne Askildsen ,  Heidi Kvande

IPC分类号： C07C231/24 ,  C07C237/46

摘要： The invention provides a method of purifying 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, comprising adding a portion of acid to a stream comprising crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide in a solvent and continuously crystallising the 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide from the crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, with removal of at least a fraction of the solvent, wherein the crystallisation is carried out in a continuous reactor, wherein the continuous reactor is a plug flow reactor. At least three further portions of acid are added to the continuous reactor during the crystallisation.

公开(公告)号：US10011560B2

公开(公告)日：2018-07-03

申请号：US15603681

申请日：2017-05-24

申请人： GE HEALTHCARE AS

发明人： Torfinn Haaland ,  Arne Askildsen ,  Rita Heskestad Kalleberg ,  Sumihar Silalahi ,  Alf Martin Farbrot ,  Inger Dagny Saanum

IPC分类号： C07C231/24 ,  C07C231/02

CPC分类号： C07C231/24 ,  C07C231/02 ,  C07C237/46

摘要： Alternative continuous downstream processes for the production of 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”) are described. Compound A is a key intermediate in the production of iodixanol and iohexol, which are two of the biggest commercially available non-ionic x-ray contrast media agents.